MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4240/wjgs.v17.i9.109980

Медицинская библиотека · World journal of gastrointestinal surgery · 2025

Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial.

Qin Xian, Chen Jing, Zhang Hua-Ni, Du Li, Ma Yan, Li Yi, Lu Yu, Wang Ya-Ting, Wu Liu-Fang, Yu Zi-Hui, Hu Meng-Jing, Li Li-Jun, Liao Bo, Li Zhen, Yang Zhi-Yong, Li Kun, Yuan Yu-Feng

Клиническое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Large number of decompensated liver cirrhosis patients in China have been diagnosed with hepatitis B virus (HBV). Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) can possibly cure decompensated liver cirrhosis because of their self-renewal and multidirectional differentiation potential.

AIM: To explore the safety and effect of treating liver cirrhosis with HBV by hUC-MSCs.

METHODS

Twenty-four participants were recruited, divided into 3 groups, and injected with different amounts of hUC-MSCs via the peripheral vein. Therapy was administered 3 times. A 24-week follow-up examination of each patient's liver function, coagulation function, general condition, and immune system was performed. Adverse events were also recorded. A 2-year survival assessment was subsequently performed.

RESULTS

Infusion therapy rapidly improved liver function. Serum albumin transiently increased on days 57 and 85 but returned to baseline by day 169, while prothrombin time activity demonstrated sustained improvement from day 29 through day 169. Interleukin-8 levels decreased persistently throughout treatment. All dosage groups achieved 100% 6-month survival; 2-year survival rates were 66.7% (low-dose), 100% (medium-dose), and 87.5% (high-dose). The interaction between dosage and efficacy was weak. Notably, the improvement in liver function was statistically significant and sustained for almost 3 months, suggesting clinically meaningful therapeutic durability.

CONCLUSION

hUC-MSCs can be considered a safe treatment for patients with decompensated liver cirrhosis associated with HBV. However, larger-scale randomized controlled trials are needed to prove its therapeutic effect.

Для цитирования: Qin Xian, Chen Jing, Zhang Hua-Ni, Du Li, Ma Yan, Li Yi, Lu Yu, Wang Ya-Ting, Wu Liu-Fang, Yu Zi-Hui, Hu Meng-Jing, Li Li-Jun, Liao Bo, Li Zhen, Yang Zhi-Yong, Li Kun, Yuan Yu-Feng. Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial.. World journal of gastrointestinal surgery. 2025. DOI: 10.4240/wjgs.v17.i9.109980.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.